Vibecotamab

DB18872InvestigationalProtein Based Therapies

Vibecotamab is under investigation in clinical trial NCT05285813 (A Phase II Study of Vibecotamab (Xmab14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure).

Mechanism: Pharmacologically active on Interleukin-3 receptor subunit alpha and T-cell surface glycoprotein CD3
Curator reviewed
Also known as: Anti-cd123 x anti-cd3 bispecific antibody xmab14045
Code names: XMAB-14045

Resolves to

Compound

UNIIJD56EJA59SCAS2138442-13-2

Targets

P26951IL3RA

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vibecotamab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account